Biomarker analysis report

2017-08-29

Contents

1	The dataset	1
2	Representativeness: Selection Bias of Biomarker Population	1
	2.1 Check selection bias in terms of key clinical variables, between full population and BEP	. 2
	2.2 Check whether the clinical outcome in BEP is comparable to the full population	
	2.3 Examine whether the prognostic/predictive/null trend of key clinical variables holds in BEP.	
	2.4 Compare treatment effect estimation in full population and in BEP, adjusted for key clinical	
	variables	
3	Biomarker property and its association to clinical variables	6
	3.1 Biomarker property and relationship to clinical variable	. 6
	3.2 Whether the biomarker shows within-arm effect	
4	Biomarker subgroup analysis	8
	4.1 Estimations within each subgroup	. 8
	4.2 KM curves	
	4.3 Check whether biomarker subgroup is confounded with key clinical variables	

1 The dataset

The dataset have 550 entries. In which 326 are in biomarker evaluable population (BEP).

Endpoint of interest: PFS Biomarker: KRAS.mutant Biomarker type: categorical

2 Representativeness: Selection Bias of Biomarker Population

In this section, we are trying to answer the question: Are biomarker evaluable population representative of the full population population?

Key baseline demographics and prognostic characteristics (including stratification variables and any variables with known prognostic effect) and efficacy outcomes should be summarized by treatment groups and compared between biomarker evaluable population (BEP) and the full population. These analyses are conducted to investigate any potential selection bias associated with the availability of the biomarker (e.g. we may not get enough tissue for patients whose tumor size is small. Therefore they may be excluded from BEP).

The key clinical biomarkers considered are:

clinical.vars.class

Sex Age
"categorical" "numeric"

2.1 Check selection bias in terms of key clinical variables, between full population and BEP


kable(SummaryVars(data=input, trt=trt, subgroup=BEP, subgroup.indicator = BEP.indicator, var=clinical.v

	All(CTRL)	BEP(CTRL)	All(TRT)	BEP(TRT)
Sex				
Total	182	103	368	223
NA's	0	0	0	0
\mathbf{F}	89 (48.9%)	47 (45.63%)	184 (50%)	111 (49.78%)
\mathbf{M}	93 (51.1%)	56 (54.37%)	184 (50%)	112 (50.22%)
Age				
N	182	103	368	223
Mean	52.54	52.93	54.03	54.27
Median	51.5	52	54	54
Min-Max	2785	$32 \dots 85$	3089	3389
NA's	0	0	0	0

2.2 Check whether the clinical outcome in BEP is comparable to the full population

The following plot compares survival outcome in BEP vs. the full population. The KM curve and 95% CI are plotted for each arm. The BEP KM curve is expected to be within the full population confidence bands.

CompareKM(data=input,tte=outcome.var[1], cen=outcome.var[2],trt=trt, bep=BEP, bep.indicator = BEP.indic



$2.3 \quad \text{Examine whether the prognostic/predictive/null trend of key clinical variables holds in BEP } \\$

The following forest plot can be used to examine whether any of the key prognostic/predictive clinical variables still show prognostic/predictive trend in BEP:

```
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
```

Across arm, Compare BEP vs. All PFS Unadjusted, unstratified analysis

Subgroup	Group	Event/N	MST	HR	(CI)	raw P	
ITT Sex(F)	CTRL	57 / 89	3.38				
	TRT	105 / 184	5.72	0.54	(0.39 – 0.74)	0.00018	
BEP Sex(F)	CTRL	33 / 47	4.11				
	TRT	64 / 111	5.59	0.53	(0.35 – 0.81)	0.0037	
ITT Sex(M)	CTRL	63 / 93	3.22				
	TRT	97 / 184	6.54	0.54	(0.39 – 0.74)	0.00012	
BEP Sex(M)	CTRL	40 / 56	3.06				
	TRT	54 / 112	6.8	0.46	(0.3 – 0.7)	0.00024	
ITT Age(>=50%, 53)	CTRL	56 / 80	3.06				
	TRT	120 / 207	5.59	0.56	(0.41 – 0.77)	0.00035	
BEP Age(>=50%, 53)	CTRL	34 / 47	3.02				
	TRT	71 / 123	6.01	0.52	(0.34 – 0.79)	0.0019	
ITT Age(<50%, 53)	CTRL	64 / 102	3.94				
	TRT	82 / 161	6.8	0.48	(0.35 – 0.67)	1.9e-05	
BEP Age(<50%, 53)	CTRL	39 / 56	4.11				
	TRT	47 / 100	6.8	0.44	(0.29 – 0.67)	0.00017	
							00.05 0.15 0.25 0.25 0.45 0.55 0.65 0.75

2.4 Compare treatment effect estimation in full population and in BEP, adjusted for key clinical variables

The following analyses show summary statistic to look at the trt/ctrl (target/reference) HR in full population and trt/ctrl HR in BEP. Both unadjusted and adjusted analyses are performed

```
kable(
   CoxTab(data=input, tte=outcome.var[1], cens=outcome.var[2], var=trt,
        var.class="categorical"),
caption="full population, unadjusted"
)
```

Table 2: full population, unadjusted

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Arm (TRT/CTRL)	0.54	0.43	0.67	7.8e-08	368	182

```
kable(
   CoxTab(data=input, tte=outcome.var[1], cens=outcome.var[2], var=c(trt, clinical.vars), var.class=c("caption="full population, adjusted for clinical variables"
)
```

Table 3: full population, adjusted for clinical variables

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Arm (TRT/CTRL)			0.66	4.1e-08	$\frac{368}{277}$	182 273
Sex (M/F) Age	$0.9 \\ 1.01$	0.72 1	$1.12 \\ 1.02$	$0.36 \\ 0.079$	211	213

```
kable(
   CoxTab(data=input.bep, tte=outcome.var[1], cens=outcome.var[2], var=trt,
        var.class="categorical"),
caption="BEP, unadjusted"
)
```

Table 4: BEP, unadjusted

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Arm (TRT/CTRL)	0.5	0.37	0.66	2.8e-06	223	103

```
kable(
   CoxTab(data=input.bep, tte=outcome.var[1], cens=outcome.var[2], var=c(trt, clinical.vars), var.class=
caption="BEP, adjusted for clinical variables"
)
```

Table 5: BEP, adjusted for clinical variables

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Arm (TRT/CTRL)	0.49	0.36	0.65	1.7e-06	223	103
Sex (M/F)	0.83	0.62	1.1	0.19	168	158

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Age	1.01	0.99	1.02	0.37		

If any selection bias is suspected, you may consider to stratify for the imbalanced factor in downstream analysis (e.g. unstratified analysis as primary analysis and stratified analysis as sensitivity analysis).

3 Biomarker property and its association to clinical variables

Relationship between the biomarker and key demographic and prognostic variables should also be investigated using bivariate plots. Prognostic property of the biomarker should also be assessed, by estimates of the clinical efficacy in the control arm.

3.1 Biomarker property and relationship to clinical variable

The following results show single variate plot for biomaker and bi-variate plots to investigate biomarker-clinical variable relationship.

```
PlotProperty(data=input, biomarker.var=bm, biomarker.class=bm.class,
                 var=clinical.vars.
                 var.class=clinical.vars.class,
                 log2=FALSE, par.param = list(mfrow=c(2,3)))
         Distribution of KRAS.mutant
                                                Distribution of KRAS.mutant by Sex
                                                                                               Age by KRAS.mutant
                                                                                                            N=231
                                                                                   2
150
                                                                                   9
100
                                                                                   20
                                          20
       Mutant (29.14%)
                       Wild Typ.. (70.86%)
```

3.2 Whether the biomarker shows within-arm effect

The following figures investigate whether the biomarker shows a within-arm effect (e.g. patients within one biomarker subgroup tend to have better clinical outcome):

```
## Some patients have missing outcome. Exclude these patients from ITT.
```

Some NAs in var column, will define the non NA entries as BEP

only 1 arm; show.itt is set to FALSE

only 1 arm; show.bep is set to FALSE

CTRL Within-arm Effect of Biomarker PFS, KRAS.mutant Unadjusted, unstratified analysis

Subgroup	Group	Event/N	MST	HR	(CI)	raw	Ρ				
KRAS.mutant(Mutant)	No	47 / 69	3.94								
	Yes	26 / 34	3.22	1.06	(0.65 – 1.74)	0.81			- -		
KRAS.mutant(Wild Type)	No	26 / 34	3.22								
	Yes	47 / 69	3.94	0.94	(0.58 – 1.53)	0.81			-		
									i	1	
							0.37	0.61	1.0 HR	1.65	2.72

- ## Some patients have missing outcome. Exclude these patients from ITT.
- ## Some NAs in var column, will define the non NA entries as BEP
- ## only 1 arm; show.itt is set to FALSE
- ## only 1 arm; show.bep is set to FALSE
- ## Warning in par(old.par): calling par(new=TRUE) with no plot

TRT Within-arm Effect of Biomarker PFS, KRAS.mutant Unadjusted, unstratified analysis

Subgroup	Group	Event/N	MST	HR	(CI)	raw F	>				
KRAS.mutant(Mutant)	No	87 / 162	6.57								
	Yes	31 / 61	6.01	0.98	(0.65 – 1.48)	0.93			_		
KRAS.mutant(Wild Type)	No	31 / 61	6.01								
	Yes	87 / 162	6.57	1.02	(0.68 – 1.54)	0.93		_	-		
							0.37	0.61	1.0 HR	1.65	2.72

The forest plots above show within-arm HR across biomarker subgroups. For a given arm, if the HR is not all around 1, it indicates that within this arm the biomarker has an association to the clinical outcome.

If similar trend is seen in both arms, it indicates that the biomarker may have a prognostic effect (the biomarker is able to identify patients with better/worse clinical outcome, regardless of treatment).

4 Biomarker subgroup analysis

4.1 Estimations within each subgroup

The following figure shows estimate of treatment effect in biomarker subgroups:

```
if(bm.class=="numeric"){
if(!is.null(numerical.finalcut)) levs <- paste0(c(">=","<"),numerical.finalcut)</pre>
if(is.null(numerical.finalcut)) {
  nm <- quantile(input.bep[[bm]], percentile.finalcut, 2) # default quantile type in forest plot functio
 numerical.finalcut <- round(nm,2) # default rounding decimal in forest plots
  levs <- paste0(c(">=","<"),percentile.finalcut*100,"%")</pre>
}
bm2 <- paste0(bm,"_group")</pre>
input[[bm2]] <- ifelse(input[[bm]] >= numerical.finalcut, levs[1],levs[2])
input[[bm2]] <- factor(input[[bm2]], levels=levs) # ">=" as Dx+
if(bm.class=="categorical") {
  bm2 \leftarrow bm
 levs <- unique(input[[bm2]])</pre>
res.2group <- PlotTabForestBiomarker(data=input,
                                   outcome.class=outcome.class,
                                    outcome.var=outcome.var,
                                    trt=trt,
                                    var=bm2,
                                    var.class="categorical",
```

```
greater=TRUE, less=TRUE,
show.itt=TRUE, show.bep=TRUE,
covariate=covariate, strata=strata)
```

Some patients have missing outcome. Exclude these patients from ITT.


Some NAs in var column, will define the non NA entries as BEP

Across-arm Effect of Biomarker PFS, KRAS.mutant Unadjusted, unstratified analysis

Subgroup	Group	Event/N	MST	HR	(CI)	raw P					
All	CTRL	120 / 182	3.25								_
	TRT	202 / 368	5.82	0.54	(0.43 – 0.67)	7.8e-08		-			
BEP	CTRL	73 / 103	3.58								_
	TRT	118 / 223	6.54	0.5	(0.37 – 0.66)	2.8e-06		_			
KRAS.mutant(Mutant)	CTRL	26 / 34	3.22								_
	TRT	31 / 61	6.01	0.48	(0.28 - 0.8)	0.0055	_	•			
KRAS.mutant(Wild Type)	CTRL	47 / 69	3.94								
	TRT	87 / 162	6.57	0.5	(0.35 – 0.72)	0.00019		-			
								0.53 1 TRT better [Hi * Unadiusted Int	•	oetter -	

4.2 KM curves

The following figure show KM curves of the biomarker subgroups:



4.3 Check whether biomarker subgroup is confounded with key clinical variables

The following table checks whether the biomarker subgroup is confounded with clinical variables. Here we check whether the clinical variable distribution is comparable in biomarker subgroups.

	$KRAS.mutant_Mutant(CTRL)$	$KRAS.mutant_Wild\ Type(CTRL)$	$KRAS.mutant_Mutant(TRT)$	$KRAS.mutant_Wild\ Type(TRT)$
Sex				
Total	34	69	61	162
NA's	0	0	0	0
F	15 (44.12%)	32 (46.38%)	35 (57.38%)	76 (46.91%)
M	19 (55.88%)	37 (53.62%)	26 (42.62%)	86 (53.09%)
Age	` ′	` ,	, ,	` '
N	34	69	61	162
Mean	51.88	53.45	54.92	54.03

	$KRAS.mutant_Mutant(CTRL)$	$KRAS.mutant_Wild\ Type(CTRL)$	$KRAS.mutant_Mutant(TRT)$	$KRAS.mutant_Wild\ Type(TRT)$
Median	52	52	$54 \\ 34 \dots 89 \\ 0$	53
Min-Max	3677	3285		3382
NA's	0	0		0

The following plot show treatment effect estimations in smaller subgroups defined by both biomarker and clinical variables. For numerical clinical variable, it is dichotomized by its median.

```
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
```

Across arm, Compare KRAS.mutant subgroup PFS

Unadjusted, unstratified analysis

